Results 151 to 160 of about 3,817,598 (310)

Human Coronavirus Infections [PDF]

open access: yes, 1995
The first report of a human coronavirus was in 1965 when Tyrrell and Bynoe (1965) isolated a virus from the nasal washings of a male child. The child had typical symptoms and signs of a common cold and the washing was found to be able to induce common colds in volunteers challenged intranasally.
openaire   +2 more sources

Mathematical Modeling of the Spread of COVID-19 in Moscow and Russian Regions [PDF]

open access: yesarXiv, 2020
To model the spread of COVID-19 coronavirus in Russian regions and in Moscow, a discrete logistic equation describing the increase in the number of cases is used. To check the adequacy of the mathematical model, the simulation results were compared with the spread of coronavirus in China, in a number of European and Asian countries, and the United ...
arxiv  

Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection

open access: yesbioRxiv, 2020
Pre-existing immune responses to seasonal endemic coronaviruses could have profound consequences for antibody responses to SARS-CoV-2, either induced in natural infection or through vaccination. Such consequences are well established in the influenza and
G. Song   +20 more
semanticscholar   +1 more source

CT Diagnosis of Coronavirus Infection

open access: yesCurrent Medical Imaging Formerly Current Medical Imaging Reviews, 2020

openaire   +2 more sources

Methods for estimating the case fatality ratio for a novel, emerging infectious disease. [PDF]

open access: yes, 2005
During the course of an epidemic of a potentially fatal disease, it is important that the case fatality ratio be well estimated. The authors propose a novel method for doing so based on the Kaplan-Meier survival procedure, jointly considering two ...
Anderson, RM   +10 more
core   +1 more source

2019 Novel Coronavirus Infection: Gastrointestinal Manifestations

open access: yesJournal of Digestive Endoscopy, 2020
The world is witnessing a major public health crisis in the wake of the third coronavirus strain pandemic, a novel coronavirus (severe acute respiratory syndrome coronavirus 2). Although initially thought to be a pure respiratory pathogen, recent reports
Jayanta Samanta   +3 more
doaj   +1 more source

Tracking COVID-19 by Tracking Infectious Trajectories [PDF]

open access: yesarXiv, 2020
Nowadays, the coronavirus pandemic has and is still causing large numbers of deaths and infected people. Although governments all over the world have taken severe measurements to slow down the virus spreading (e.g., travel restrictions, suspending all sportive, social, and economic activities, quarantines, social distancing, etc.), a lot of persons ...
arxiv  

Time Kinetics of Viral Clearance and Resolution of Symptoms in Novel Coronavirus Infection

open access: yesAmerican Journal of Respiratory and Critical Care Medicine, 2020
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; previously called “2019-nCoV”; the virus that causes coronavirus disease [COVID-19]) has infected .1,773,000 patients and killed .111,650 people worldwide as of April 13, 2020 (1).
De Chang   +9 more
semanticscholar   +1 more source

Middle East respiratory syndrome coronavirus in pediatrics: a report of seven cases from Saudi Arabia [PDF]

open access: yes, 2018
This article is made available for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source.
Al-Tawfiq, Jaffar A.   +3 more
core   +1 more source

N-glycoproteomic profiling revealing novel coronavirus therapeutic targets potentially involved in Cepharanthine's intervention

open access: yesMedicine in Novel Technology and Devices, 2022
The Coronavirus disease 2019 (COVID-19) has posed a serious threat to global health and the world economy. Antiviral therapies targeting coronavirus are urgently required. The Cepharanthine (CEP) is a traditional Chinese herbal extract.
Wenlin An   +4 more
doaj  

Home - About - Disclaimer - Privacy